3r4l: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
[[Image:3r4l. | [[Image:3r4l.png|left|200px]] | ||
{{STRUCTURE_3r4l| PDB=3r4l | SCENE= }} | {{STRUCTURE_3r4l| PDB=3r4l | SCENE= }} | ||
===Human very long half life Plasminogen Activator Inhibitor type-1=== | ===Human very long half life Plasminogen Activator Inhibitor type-1=== | ||
{{ABSTRACT_PUBMED_21947232}} | {{ABSTRACT_PUBMED_21947232}} | ||
==About this Structure== | ==About this Structure== | ||
[[3r4l]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3R4L OCA]. | [[3r4l]] is a 1 chain structure of [[Plasminogen activator inhibitor]] with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3R4L OCA]. | ||
==See Also== | |||
*[[Plasminogen activator inhibitor|Plasminogen activator inhibitor]] | |||
==Reference== | ==Reference== |
Revision as of 21:36, 25 July 2012
Human very long half life Plasminogen Activator Inhibitor type-1Human very long half life Plasminogen Activator Inhibitor type-1
Template:ABSTRACT PUBMED 21947232
About this StructureAbout this Structure
3r4l is a 1 chain structure of Plasminogen activator inhibitor with sequence from Homo sapiens. Full crystallographic information is available from OCA.
See AlsoSee Also
ReferenceReference
- ↑ Jankun J, Yang J, Zheng H, Han FQ, Al-Senaidy A, Skrzypczak-Jankun E. Remarkable extension of PAI-1 half-life surprisingly brings no changes to its structure. Int J Mol Med. 2012 Jan;29(1):61-4. doi: 10.3892/ijmm.2011.798. Epub 2011, Sep 22. PMID:21947232 doi:10.3892/ijmm.2011.798
- ↑ Chorostowska-Wynimko J, Swiercz R, Skrzypczak-Jankun E, Wojtowicz A, Selman SH, Jankun J. A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis. Mol Cancer Ther. 2003 Jan;2(1):19-28. PMID:12533669
- ↑ . PMID:019082507